Lornoxicam (I) (6-chloro-4-hydroxy-2-methyl-N-2-pyridyl-2Hthieno[2,3-e]thiazine-3-carboxamide-1,1-dioxide) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. 1 It is distinguished from established oxicams by a relatively short elimination half-life, which may be advantageous from a tolerability standpoint. 2 Increasingly, the monitoring of drugs is being considered a rational approach for the correct management of patient therapy. Regarding lornoxicam, attention must be given in this respect, because determining the relationship between the drug dose and the drug levels imparts an important aspect concerning the success of the treatment.
Lornoxicam (I) (6-chloro-4-hydroxy-2-methyl-N-2-pyridyl-2Hthieno[2,3-e]thiazine-3-carboxamide-1,1-dioxide) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. 1 It is distinguished from established oxicams by a relatively short elimination half-life, which may be advantageous from a tolerability standpoint. 2 Increasingly, the monitoring of drugs is being considered a rational approach for the correct management of patient therapy. Regarding lornoxicam, attention must be given in this respect, because determining the relationship between the drug dose and the drug levels imparts an important aspect concerning the success of the treatment.
Accordingly, chromatographic methods employing ultra-violet and electrochemical detection have been reported for determining the drug in biological fluids. 3, 4 A literature survey revealed that no attempt has been made to study the voltammetric behavior of lornoxicam. However, the polarographic and adsorptive behaviors at a hanging mercury drop electrode of two oxicams, piroxicam and tenoxicam, have been reported. [5] [6] [7] [8] [9] Differential pulse polarography has been used for the piroxicam determination in drug formulation and in urine. 7 Square-wave (SW) and square-wave adsorptive stripping voltammetric determinations at a hanging mercury drop electrode have also been employed for the determination of piroxicam and tenoxicam in urine. 8 Recently, the differential-pulse polarographic determination of tenoxicam in blood has been reported. 9 The objective of the work described in this paper was to investigate the electrochemical behavior of lornoxicam and devise a suitable square-wave voltammetric method for the analysis of lornoxicam in spiked serum samples.
Experimental

Apparatus
All voltammograms were obtained with a 394-PAR Electrochemical Trace Analyzer, coupled with a PAR 303A static mercury drop electrode (drop size, medium; area of the drop, 0.017 cm 2 ). A polarographic cell bottom was fitted with an Ag/AgCl/saturated KCl reference electrode and a platinum wire as a counter electrode. A magnetic stirrer (PAR 305) and a stirring bar provided a convective transport during accumulation. Data handling and storage were controlled by a computer and 394 software. All voltammograms were stored as ASCII files for later representation and manipulation with the ORIGIN 4.1 program. The following parameters were used throughout, unless otherwise stated: for a cyclic scan, a scan rate of 100 mV s -1 ; for a differential-pulse scan, a pulse amplitude of 50 mV and a scan rate of 50 mV s -1 ; and for a square-wave scan, a frequency (f) of 100 Hz, a scan increment (dE) of 10 mV and an amplitude (Esw) of 25 mV.
Chemicals
Lornoxicam was supplied by Hafslund Nycomed Pharm (Austria). A stock solution of 1.0 × 10 -3 M lornoxicam was prepared in methanol and stored in the dark at 40˚C. More dilute solutions were prepared daily with deionized water just before use.
Supporting electrolyte solutions e.g. Britton-Robinson, acetate buffers and perchloric acid, were prepared in deionized water using analytical-grade reagents.
Procedure
A 10 ml volume of the supporting electrolyte solution (usually 0.05 M perchloric acid) was transferred to the cell and deaerated with nitrogen for 10 min (and for 30 s before each adsorptive cycle). The accumulation potential was then applied to a new mercury drop for a selected time, while the solution was stirred at 400 rpm. The stirring was then stopped, and after 2 s rest the voltammogram was recorded by applying a negative-going square-wave scan. After background voltammogram had been recorded, aliquots of the drug standard were introduced into the cell and the adsorptive stripping cycle was repeated using a new mercury drop. All data were obtained at ambient temperature. To a 0.5 ml serum sample, 1.0 ml perchloric acid (0.1 M) was added. The mixture was centrifuged for 3 min at 4000 rpm. Then, the protein precipitate was discarded and an aliquot (200 µl) of the clear solution was added to 10 ml of 0.05 M perchloric acid and transferred to a voltammetric cell. The solution was deaerated for 10 min; after a 2 s rest, a squarewave pulse scan towards more negative potential values was applied. For a calibration graph, lornoxicam was added to 0.5 ml of serum to obtain final concentrations ranging from 5.0 × 10 -10 to 1.85 × 10 -8 M in the voltammetric cell (i.e. about 25 to 1025 ng ml -1 serum in the original samples). The voltammetric procedure was continued as described above. A calibration graph was generated by a least-squares regression of the peak current against the concentration of the analyte.
Recovery experiments
In order to carry out recovery experiments, known amounts of lornoxicam were added to serum samples prior to sample treatment. Then, the sample pretreatment was performed. With an aliquot of the pretreated sample the voltammetric procedure was continued as described before. The concentrations of lornoxicam in serum were derived from the calibration graph. The relative recovery was calculated by comparing the concentration of the drug found with the actual added concentrations.
Results and Discussion
Cyclic voltammetry
To investigate the adsorptive behavior of lornoxicam at HMDE, a cyclic voltammogram of 1.0 × 10 -5 M lornoxicam in 0.05 M perchloric acid solution was recorded after 10 s of stirring at -0.6 V vs. Ag-AgCl-KCls. Two cathodic peaks, corresponding to the reduction of the adsorbed drug, were observed at -0.915 and -1.028 V, respectively ( Fig. 1 ). Also shown (dotted line) is the analogous response without any prior accumulation. A substantially smaller reduction peak corresponding to the dissolved species was observed. This behavior implies that the adsorption of lornoxicam at a mercury surface is a very fast process, and that equilibrium is attained within a few seconds. A shoulder preceding the first peak was also observed. The intensity of this shoulder was proportional to the scan rate, demonstrating its capacitive origin. For quantitative purposes, the second peak at -1.028 V is most useful, and therefore the rest of this study was concentrated on this peak. No peaks were observed in the anodic branch, indicating that lornoxicam reduction is an irreversible process. Such reduction peaks were attributed to a two-electron transfer, given to the opening of the thiazine ring, followed by twoelectron reduction of the double bond of the enol functions. 6 Also, the adsorption effect was identified by a log-log plot of the stripping peak current vs. scan rate. The peak increased linearly between 25 to 250 mV s -1 with a correlation coefficient of 0.997. Moreover, the peak potential shifted linearly to a more negative potential when the scan was increased, which confirmed the irreversibility of the reductive process.
The dependence of the adsorptive stripping peak current on the accumulation time was tested at two concentration levels, i.e., 1 × 10 -8 M and 1.0 × 10 -7 M, using a square-wave form. The resultant curves are shown in Fig. 2 . As expected, the lower is the bulk concentration of the drug, the lower is the magnitude of the stripping current, and the better is the linear relationship between the peak intensity and the accumulation time. Because either the accumulation time or the assayed concentration takes higher values, the peak current ceases to increase. In fact, it shows a trend to diminishing values that can even drop close to those achieved after a very short accumulation time. This could be explained in terms of the release of a large amount of the adsorbed lornoxicam molecules from the electrode surface. Similar phenomena have been reported for a similar antiinflammatory oxicam drug, tenoxicam. 8 The accumulation potential is also a major factor which affects the response sensitivity. The effect of the accumulation potential (Eacc) on the square-wave adsorptive peak current (ip) of 5.0 × 10 -8 M lornoxicam for an accumulation time of 30 s over the range -0.1 to -0.8 V (vs. Ag-AgCl) was evaluated. Figure 3 shows that the optimal accumulation potential is between -0.5 and -0.7 V. The sensitivity decreases sharply at potentials less than -0.7 V. Thus, an optimal accumulation potential of -0.6 V was used in subsequent studies to obtain the shortest scan range or to achieve the most optimum measurement speed.
The conditions of the electrolyte, such as types of electrolyte and pH, are additional key factors that affect the sensitivity of stripping voltammetry. The types of electrolytes include 184 ANALYTICAL SCIENCES FEBRUARY 2002, VOL. 18 The adsorptive behavior of the drug under investigation was studied by comparing two different scan modes, i.e. differential-pulse and square-wave voltammetry. Using the square-wave mode, we applied high scan rates to avoid desorption of the drug while measuring the peak current. The optimum instrumental parameters of SW were then chosen from a study of the variation of the peak current of 5.0 × 10 -8 M lornoxicam in 0.05 M perchloric acid after accumulation at -0.6 V for 30 s with the frequency, scan speed and pulse height. Higher peak currents were observed with high frequency on the order of 120 Hz, or by increasing the pulse height from 25 to 100 mV. The peak increases linearly with the scan increment up to 10 mV. The best peak definition was found with 120 Hz frequency, a 10 mV scan increment and a 25 mV pulse height.
Calibration plots have been established with different accumulation times, i.e. 15, 30 and 45 s ( Table 1 ). In spite of the desorption described above, linearity could be extended even over 5.0 × 10 -7 lornoxicam. The detection limits of lornoxicam have been calculated from the calibration curves as 3Syx/b. 11 The reproducibility of the method was determined by successive measurements of ten lornoxicam solutions of 1 × 10 -8 M after accumulation at -0.6 V for 30 s. The coefficient of variation was 2.1%.
Lornoxicam assay in spiked serum
A square-wave measurement following an accumulation time of more than 5 s in a solution containing serum led to reductive peaks with a significant depression of their heights compared with a measurement performed without accumulation. This might in part be due to desorption of the drug; the other part may be attributed to adsorbing substances, competing with lornoxicam for the adsorption sites at the electrode surface. As a consequence, direct-current measurements, i.e. square-wave voltammetry without accumulation, were preferable in such analysis. Figure 4 illustrates the square-wave voltammetric response to different concentrations of lornoxicam in serum samples. The resulting calibration graph is shown also (inset). The peak current was linearly related to the lornoxicam concentration over the range 5.0 × 10 -10 to 1.85 × 10 -8 M in the voltammetric cell (i.e. about 25 to 1025 ng ml -1 serum in the original samples) according to the following equation: ip (µA) = 0.564 + 0.153C (nM), r = 0.9994%. The estimated detection limit was 1.0 × 10 -10 M, which corresponds to 5.4 ng of lornoxicam per ml of serum. Recovery experiments were carried out by adding the drug to serum samples to achieve low, medium and high concentrations of linear range (i.e. 50, 500 and 1000 ng ml -1 ) and analyzing three samples of each concentration. The average recoveries of lornoxicam were more than 95% with a coefficient of variation of less than 3.0%. The precision of the results in serum was evaluated for five samples spiked with lornoxicam at a concentration of 100 ng ml -1 , resulting in a coefficient of variation of 2.7%.
The 5′-hydroxy metabolite is known to be the main metabolite of lornoxicam in human serum. 10 It should be noted that the 5′hydroxy metabolite can not be differentiated from the intact compound using the voltammetric method, since hydroxylation of the pyridyl ring does not affect the reduction potential of the double bond in the thiazine ring, as previously demonstrated. 7 For applying the proposed method to the analysis of lornoxicam in serum, a separation step may be needed to avoid interference of the drug metabolite.
The serum levels of lornoxicam after a normal therapeutic dose were reported to be in the approximate range of a few tens to several hundreds ng per ml serum, 4 and in all cases above the lower limit of the proposed square-wave voltammetric method. Square-wave voltammetry permits the rapid determination of lornoxicam with relatively inexpensive instrumentation. Moreover, no manipulation of the serum sample other than protein precipitation by perchloric acid, which was used as a 185 ANALYTICAL SCIENCES FEBRUARY 2002, VOL. 18 supporting electrolyte, was required. All of these facts greatly demonstrate the proposed method to be well suited for serumlevel monitoring in clinical practice and pharmacological studies.
